DCT Advisors Approve $22 Mil. Set Aside For Interactive R01s Systemic Therapies
In Brief: NCI Awards 4 Contracts For Enrichment Program; Dana-Farber Names Breast Center Leadership
NIH Authorization Set For Another Try; Women’s Cancers Are Targeted
DCT Advisers Ok Expansion of Phase 1, Phase 2 Testing
More DCT Concepts Approved By Advisors
Taxotere Encouraging, CPT-11, Other Agents Entering Trials; Chabner
Procedures For Ending IGs Announced
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says - Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - The Galleri MCD vote: What FDA asked its advisors to ignore
